Pages
- About Us
- Accessibility
- Advocacy
- ALS Canada Honour Wall
- Diagnosis
- Frequently Asked Questions
- Healthcare Professionals
- How much do you know about ALS?
- News
- Our nationwide network of ALS Association care teams and other partners provide people living with ALS and their family and loved ones with support in communities across the country.
- Privacy Policy
- Research
- Resources
- We are united in our pursuit of a world free of ALS
- Webinars and Education
- Get Support
- Take Action
- Home
- What is ALS?
- Managing ALS
News
- Celebrating ALS Research Funding: 2025 CIHR Grants Announcement
- Five students impacted by ALS receive the 2025 ALS Canada Kevin Daly Bursary
- ALS Canada welcomes ALS National Genetic Counsellor to lead pilot project
- Inside the Science: The journey of clinical trials and off-label treatments
- ALS Canada invests in Access ALS to position Canada as a global leader in clinical trials
- Research Update, August 2025
- From the Research Desk – July 2025
- ALS Canada Advocacy Update, April - June 2025
- Envisioning the future of ALS research in Canada
- Driving Discovery: decades of fuelling ALS research across Canada
- Engaging with elected officials: ALS advocacy 101
- Guided by lived experiences: ALS Canada welcomes five new Board Members
- ALS Canada bids four Board members farewell with gratitude and thanks
- ALS Canada calls for national recognition during ALS Awareness Month
- Applications now open for the 2025 ALS Canada Kevin Daly Bursary
- Inside the Science: Imaging and ALS
- Research Update, April 2025
- Driving Discovery: Canada’s role in the journey to Qalsody’s approval
- ALS Canada Advocacy Update, January - March 2025
- From the Research Desk – March 2025
- ALS Canada and Brain Canada invest in the future of ALS research with the 2024 Career Transition Award
- 39 members of the Canadian ALS community honoured with King Charles III Coronation Medal
- ALS Canada launches new Children and Youth Resource Hub to help families share information
- ALS Canada submits patient input submission for Canada’s Drug Agency’s review of QALSODY (tofersen)
- ALS Canada and Brain Canada invest more than $1.1 million to fuel discoveries and understanding of ALS
- QALSODY (tofersen injection) approved as a treatment for SOD1-ALS in Canada with Conditions
- Inside the Science: Brain-Computer Interface and ALS
- Supporting advancements in ALS care with the 2024 Mitsubishi Tanabe Pharma Canada Fellowship
- ALS Canada Advocacy Update, October-December 2024
- Research Update, January 2025
- Canada’s Drug Agency launches call for patient input on tofersen
- Global leaders in ALS/MND gather for a week of learning, sharing, and collaboration in Montreal
- ALS Canada and Brain Canada invest more than $700,000 in funding to strengthen the future of ALS research and care
- Celebrating Dr. Richard Robitaille, recipient of the Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing
- ALS Canada Buck-A-Puck for ALS: Uniting the hockey community to raise awareness and funds for ALS research
- ALS Canada and ALS Quebec to host global leaders for a week of international meetings on ALS/MND
- ALS Society of Canada contributes to global research efforts with support of AMP® ALS
- ALS Canada announces first-of-its-kind National ALS Genetic Counsellor with funding from TD Bank Group
- ALS Canada’s Canadian ALS Learning Institute (CALI) recognized for innovation, creativity, and impact
- The ALS Society of Canada celebrates $13 million investment into Ontario Provincial ALS Program
- Strength in the community: ALS Canada Pull to End ALS fundraiser returns
- Mitsubishi Tanabe Pharma Canada announces the discontinuation of RADICAVA IV (edaravone)
- ALS Canada Research Update, October 2024
- ALS Canada Advocacy Update July-September 2024
- Cyclists gear up for the ALS Canada Revolution Ride in support of people living with ALS
- Four students affected by ALS receive the ALS Canada Kevin Daly Bursary
- Meeting an urgent need: Why it’s important now more than ever to give
- Join the global movement: ALS Canada calls on Canadians to take the plunge and continue the momentum of the Ice Bucket Challenge
- ALS Canada Advocacy Update – April-June 2024
- Letter to the Federal Minister of Transport on the accessibility of air travel for passengers using mobility devices
- ALS Canada and ALS Quebec co-host the international ALS/MND community in Montreal
- United in ALS this June ALS Awareness Month
- Welcoming the newest ALS Canada’s new Board of Directors
- ALS Canada expresses gratitude and thanks to our four departing Board members in 2024
- 2024 ALS Canada Research Forum
- New ALS discovery at Western University
- ALS Canada Kevin Daly Bursary is now accepting applications for post-secondary students affected by ALS
- National Volunteer Week: Every Moment Matters
- ALS Canada Advocacy Update – January-March 2024
- TUDCA trial did not meet its endpoints
- Amylyx announces formal intention to remove ALBRIOZA from the market
- Update on 2024 Ontario Budget Announcement
- Health Canada Accepts New Drug Submission for tofersen
- PHOENIX Trial of AMX0035 did not meet endpoints
- Funding discoveries in ALS research: ALS Canada and Brain Canada announce more than $1.3 million for 2023 Discovery Grants
- Health Canada issues a Notice of Non-Compliance–Withdrawal for masitinib
- ALS Canada and Brain Canada invest in future leader of ALS research with 2023 Career Transition Award
- ALS community calls on the Ontario government to invest $6.6 million in Budget 2024 to address urgent disparities in access to ALS services and care
- Toronto Star op-ed recognizes disparities in Ontario health care system for people living with ALS
- ALS Society of Canada recognizes innovation and need for expedited funding in new Acceleration Grant Program
- Ontario Provincial ALS Program: Enhancing care and quality of life of people living with ALS
- Negative results from Phase 3 ADORE clinical trial of Oral Edaravone (FAB122) in ALS
- You can support ALS Canada & enjoy tax benefits!
- All provinces are listing RADICAVA Oral Suspension (edaravone)
- ALS Canada Advocacy Update – October-December 2023
- We’re closer than ever…but we’re not there yet
- An exciting GivingTuesday announcement!
- ALS Canada and Brain Canada invest more than half a million dollars in the future of ALS researchers with the 2023 Clinical Research Fellowship and Trainee Awards
- ALS Canada Research Update, October 2023
- Challenging ourselves for change: September events wrap up
- ALS Canada Advocacy Update – July-September 2023
- Gear up for change on September 24 for ALS Canada’s Revolution Ride
- Empowering resilience and academic pursuits
- ALS Canada pulling to make a difference
- Meet nine Canadian researchers moving ALS research forward with the help of the ALS Canada-Brain Canada Discovery Grant Program
- Meet nine Canadian researchers moving ALS research forward with the help of the ALS Canada-Brain Canada Discovery Grant Program
- RADICAVA Oral Suspension (edaravone) listed on the Provincial Drug Formulary in Ontario
- ALS Canada Research Update, July 2023
- Mitsubishi Tanabe Pharma Canada announces the conclusion of the pCPA negotiations for RADICAVA Oral Suspension (edaravone)
- ALBRIOZA listed on the Provincial Drug Formulary in Ontario
- Amylyx announces the conclusion of the pCPA negotiations for ALBRIOZA
- ALS Canada Advocacy Update – April-June 2023
- ALS Canada thanks outgoing Board member for dedication to our shared cause
- ALS Canada welcomes two new Board members in 2023/24
- Making ALS a priority, today and tomorrow
- Applications open for ALS Canada Kevin Daly Bursary in support of Canadian students touched by ALS
- Qalsody (tofersen) has been approved in the United States and the European Union as a treatment targeting a genetic cause of ALS
- ALS Canada Research Update, March 2023
- ALS Canada and Brain Canada invest more than $1.4 million in ALS research grants
- The Federal Government announces the National Strategy for Drugs for Rare Diseases
- ALS Canada Advocacy Update – January- March 2023
- A day for action for the Rare Disease community
- ALS Canada Advocacy Update – October – December 2022
- You’re supporting the ALS community today and tomorrow
- Major investment in top talent in ALS research
- Health Canada approves Radicava (edaravone) Oral Suspension for use in Canada
- ALS Canada to host information on IMD Health to improve quality of health education for people living with ALS
- ALS Canada Advocacy Update – July – September 2022
- ALS Canada Pull to End ALS
- ALS Canada Research Update, September 2022
- ALS Canada thanks outgoing Board members for commitment to our shared cause
- ALS Canada welcomes three new Board members in 2022/23
- A novel collaboration brings decades of expertise to ALS research
- Alberta man first to be recruited for CAPTURE (Comprehensive Analysis Platform To Understand, Remedy, and Eliminate) ALS
- Driving momentum: 2021 Annual Report to the community
- ALS Canada Advocacy Update – April – June 2022
- ALS Canada Research Update, June 2022
- AMX0035 approved as a treatment for ALS in Canada with Conditions
- ALS Awareness Month brings access to treatments in Canada to the forefront
- Health Canada Accepts Supplement to a New Drug Submission and Grants Priority Review for Oral edaravone
- Knowing the issues that matter to Ontario’s ALS Community: 2022 Ontario Election
- Breaking Down Barriers to Accessing Therapies: Changes to PMPRB Regulations
- ALS Canada invests more than $800,000 in the future of ALS research
- ALS Canada Advocacy Update – January-March 2022
- ALS Canada Research Update, March 2022
- ALS Canada Marks Rare Disease Day 2022 By Calling on Ontario to Champion Expedited Access to ALS Therapies
- $1.125 million investment to advance understanding, diagnosis and treatment of ALS
- CADTH launches call for patient input on oral edaravone
- Top Research Stories of 2021
- ALS Canada Advocacy Update – December 2021
- All Provinces Now Listing Radicava (edaravone)
- Learning from COVID-19 to strengthen support for Ontarians living with ALS
- Make Your Voices Heard: Your Input is Needed for Review of New ALS Therapy
- CADTH launches call for patient input on AMX0035
- Phase 3 Valour results for tofersen presented by Biogen
- ALS Canada Research Update, October 2021
- ALS Canada Advocacy Update – October 2021
- Knowing the issues that matter to the ALS Community: ALS Election Commitments
- ALS Canada Advocacy Update – August 2021
- ALS Canada Research Update, June 2021
- ALS Canada Advocacy Update – June 2021
- ALS Canada Strengthens Board of Directors with four new appointments in 2021/22
- ALS Canada Advocacy Update
- ALS Canada thanks outgoing Board members for their commitment to a future without ALS
- New $2.85M grant to push ALS research forward
- Provide your input into shaping a national strategy for rare disease drugs
- Collaboration in Pursuit of a Future Without ALS: $1 Million Invested in ALS Research
- Top Research Stories of 2020
- ALS Research Update, November 2020
- Ice Bucket Challenge Proceeds Help Fund First Canadian ALS Care and Management Guideline
- ALS Doesn’t Stop – So Neither Can Research Investment
- Long-Term Data for CENTAUR clinical trial of AMX0035 supports a further possible benefit for people with ALS
- Phase 2 CENTAUR clinical trial for AMX0035 shows promising results
- ALS Research Update, August 2020
- Promising results from Phase 1/2 clinical trial of tofersen
- ALS Canada welcomes three new Board members in 2020/21
- ALS Canada thanks outgoing Board members for dedication to our shared cause
- Together we are stronger: The ALS community takes to Ottawa
- Ice Bucket Challenge continues to drive research discovery by providing new insights into ALS
- ALS Research Update, May 2020
- ALS Research Update, May 2020
- Top 10 Research Stories of 2019
- ALS Canada Invests Almost $1.4 Million Towards Innovative ALS Research Projects In Pursuit of a Future Without ALS
- ALS Research Update | October 2019
- ALS Research Update | October 2019
- What’s all this FUS about? A new way of delivering future ALS treatments is off to a good start.
- ALS Research Update | August 2019
- Because Of You: ALS Canada’s 2018 Annual Report
- Augie’s Quest and ALS Research in Canada
- ALS Research Update | March 2019
- What’s the story with CuATSM
- ALS Research Matters
- Top 10 research stories of 2018
- Remembering our friend, Eddy Lefrançois
- ALS Society of Canada dedicates last of the matched Ice Bucket Challenge research funding to early-career researchers in pursuit of a future without ALS
- Thanks to donor generosity ALS Canada invests $1 million in innovative Canadian ALS research to provide a greater understanding of ALS
- ALS Research Update, October 2018
- Health Canada has approved Radicava (edaravone), a second ALS treatment for Canadians
- Power in Numbers
- The impact of donor dollars on ALS research in Canada
- A Community Connected
- Radicava (edaravone): Make your voice heard
- ALS Research Update, June 2018
- Ice Bucket Challenge funded research published in scientific journal “Cell”
- The ALS Association Partners with the Motor Neurone Disease Association and the ALS Society of Canada to Establish the ALS Reproducible Antibody Platform
- ALS Research Update, February 2018
- Most newsworthy research stories of 2017
- ALS Canada awards $3 million for 12 new research projects to help make amyotrophic lateral sclerosis (ALS) a treatable, not terminal disease
- New Board appointments in 2017/18
- ALS Research Update, November 2017
- ALS Research Update, August 2017
- Now available: ALS Canada’s 2016 Annual Report
- MPs give ALS a voice in Parliament
- A second ALS treatment, edaravone, has been newly approved in the United States
- New Canadian investments in ALS research reflect growing knowledge about the disease and increasing likelihood of effective treatments being developed
- Canada’s rising stars in ALS research receive more than $1 million from the ALS Canada Research Program and Brain Canada
- Ice Bucket Challenge leads to ALS gene discovery
- Government of Canada has announced the activation of the extension of the Compassionate Care Benefit (CCB) from six to 26 weeks
- New bona fide ALS gene discovered by international group of researchers
Resources
- Tell the federal government to invest in ALS research
- Canadian Collaboration to Cure ALS
- Welcome to Parliament: A Message from Canada’s ALS Community
- Ontario Provincial Program: Thank you letter-writing campaign
- Children and Youth Hub
- Federal Election 2025
- Ontario Provincial ALS Program: A proactive solution for enhancing ALS care in Ontario
- Ontario Election 2025
- ALS Canada's How to Read a Press Release
- ALS Canada Genetics Glossary
- Travelling with ALS
- Sexuality, intimacy, and ALS
- Primary lateral sclerosis
- Palliative care and end-of-life planning in ALS
- Kennedy's disease
- Caring for Yourself: Information for caregivers
- ALS Canada Equipment Catalogue
- Clinical Trials Frequently Asked Questions
- The Time Is Now. An Urgent Call For Expedited & Equitable Access To ALS Therapies.
- ALS Canada Community Advocacy Toolkit
- ALS Canada Advocacy in a Box Toolkit
- First steps after an ALS diagnosis
- ALSC Donation Form
- Canadian Best Practice Recommendations For The Management Of Amyotrophic Lateral Sclerosis: Establishing a national standard for ALS care and treatment in Canada
- ALS Canada Volunteer Application Form
- ALS Canada Gene Hub
- Talking with Your Patient’s Children About ALS
- A Guide to ALS Patient Care for Primary Care Physicians
- ALS and genetics
- ALS Guide: A resource for people living with ALS
- Cannabis and ALS
- Feeding tubes
- ALS & constipation
- Ventilation: Options and decision making
- ALS & cognitive changes
- Pain and ALS
- ALS, MS, and MD: How do they differ?
- Bulbar ALS
- ALS quick facts
- Coping With Grief: Strategies For People Living With ALS
- ReferALS Early Referral Tool
- Advocacy Toolkit
- For schools: Talking with young people about ALS
- Conflict of interest and non-disclosure agreement for peer, reviewers, committee members, and observers
- Guide to Reading Research Papers
- The ‘How To’ Health Guide
- ALS Canada Research Glossary
- Canadians living with ALS unite to CAPTURE ALS
- Frequently Asked Questions – ALBRIOZA (AMX0035)
- Bonus Session | 2021 ALS Canada Research Forum
- ALS Canada Webinar: Update on ALS clinical trials in Canada and around the globe
- How new drugs become approved and accessible to Canadians
- Oh the humanity: A look at modeling human ALS in the lab
- Stay on target: Moving promising avenues closer to the clinic
- ALS Top Model: Runway to success
- Can lower animal models take us higher? A look at worm, fish, flies and more in ALS
- June 2020 PMPRB Draft Guidelines
- ALS Canada community support services continue to evolve during COVID-19
- ALS Awareness Month 2020: Update on global ALS clinical trials
- Understanding the Issues: 2019 Federal Election Health Commitments
- Creating a foundation for future therapies: The need for antibody validation in ALS research
- The ALS Ice Bucket Challenge and the changed landscape of ALS research in Canada
- How you can fundraise for ALS Canada through Facebook
- An update on clinical trials in Canada and around the world | Part two
- An update on clinical trials in Canada and around the world | Part one
- Ask the Experts
- Holiday Gift Ideas
- An Unlikely Suspect in ALS: Inhibitory Homeostasis
- Modeling ALS using patient-derived motor neurons and glia
- Zebrafish models of ALS
- The epigenetic study of age acceleration in C9orf72 carriers
- ALS steering wheel
- Breaking barriers, connecting brains to machines
- The biomarker challenge in ALS
- Project MinE: the new genetics of MND
- How does the skin of people living with ALS differ from the skin of others?
- Power in Numbers
- New clinical trials for Canadians with ALS
- Can exposure to toxins and other environmental factors play a role in the development of sporadic ALS?
- Approaches for better modeling of human disease
- How touchscreen technology may help to identify cognitive impairments in ALS mice and pave the way for future treatments
- A webinar by Neurologists for Canadians affected by ALS
- Communicating an ALS diagnosis
- Holiday gift ideas for someone living with ALS
- Protein misfolding in ALS
- Lazarus by Lunasin? Untangling an ALS X-file
- Getting to know pimozide in ALS
- Biomarkers for C9orf72-associated ALS
- Understanding the role of the neuromuscular junction in ALS
- The role of ataxin-2 in ALS
- Cannabinoid use in ALS
- Skin models for the study of ALS
- Masitinib for the treatment of ALS
- Cognition in ALS – it’s not what you think
- Research to help people with ALS stay active and independent
- Finding New Ways to Diagnose ALS Faster with Advanced Imaging
- Maximizing the impact of donor dollars for ALS research
- ALS researchers respond to the Ice Bucket Challenge
- ALS Canada Webinar Series: Clinical Trials
- Q&A with Dr. David Taylor, VP, Research
- ALS Canada Webinar Series: Research Update
- Could state-of-the-art gene editing play a role in correcting genetic mutations linked to the development of ALS?
Stories
- Get ready to help send a united message to the federal government.
- Tri’ing to End ALS: Couple on cross-Canada triathlon tour to raise funds for ALS
- In My Words: Dave Silva
- Championing equitable access: Miriah’s advocacy story
- "You’ll know it was all worth it": Taking a swing at fundraising
- Powering discovery: why ALS Awareness Month matters more than ever
- Annual Report 2024: United in building partnerships
- Annual Report 2024: United in community support
- Annual Report 2024: United in impact
- Annual Report 2024: United in collective efforts
- In My Words: Charlotte Manser
- Beyond the diagnosis: my experience navigating ALS
- Honoring a legacy: Patricia's tribute to Yuri through ALS Canada
- In My Words: Bill Duff
- Honouring Lisa: The Bertolo/Sallows family's ALS fundraising journey
- In My Words: Amanda Tam
- Empowering future leaders: Meet the 2024 ALS Canada Kevin Daly Bursary recipients
- Your support unites us in a world free of ALS
- Coming together for change: Highlights from our 2024 fall events
- In my words: Jennifer Hutton
- Get ready: GivingTuesday is coming
- United in knowledge – elevating ALS understanding together
- Advocating for change: how we're shaping ALS policy
- How we support the ALS community – every step of the way
- Leading the charge in ALS research
- Exciting news from ALS Canada
- In my words: Steven Gallagher
- Annual Report 2023: Improving quality of life
- Annual Report 2023: Bringing the community together
- Annual report 2023: Empowering informed decisions
- Annual Report 2023: Supporting the ALS community
- United in our memory
- Messages from our community
- A letter from Mehboob - “You’ve given me strength and hope”
- Daniella D’Amici demonstrates resourcefulness and resilience in the face of adversity
- 2023 ALS Canada Kevin Daly bursary recipient Sarah Jacob has her sights set on change
- Catherine Brassard exhibits steadfast determination to further her medical studies in the face of ALS
- Memories of my father
- Changing the future of ALS: It’s not a matter of “if” but “when”
- Can we reprogram cells we already have to replace neurons damaged by ALS? This postdoctoral fellow wants to find out
- PhD student Lucia Jadon opens new pathways for ALS research
- Charlotte Manser is turning her grief into hope for other families facing ALS
- Award fills funding gap for international student exploring understudied causes of ALS
- Funding allows a future change-maker in ALS to pursue innovative research
- Dr. Alex Parker: Not giving up on the “hard problem” of ALS
- Dr. Gary Shaw: Exploring how cells “take out the trash” to find new therapeutic targets in ALS
- Dr. Maria Vera Ugalde: Exploring a cellular mystery: why our bodies “paramedics” don’t work well in motor neurons
- Dr. Christine Vande Velde: Keeping the mission “front of mind”
- Dr. Carlos Rodrigo Camara-Lemarroy: Shortening the timeline for accessible, translatable ALS treatments
- Drs. Maria Stepanova and Holger Wille: Two researchers bring together diverse expertise, from physics to structural biology, to find new insights
- Dr. Thomas Durcan: 3D brain models will give new insights into ALS
- Dr. Renée Douville: How dormant retroviruses could open new targets for ALS treatment
- Dr. Richard Robitaille: Building on ten years of momentum fueled by Discovery Grants
- 2023 ALS Canada Research Forum: Cultivating connection and collaboration between the world of research and community experience
- Climbing for a cure
- “While I still can, I will inspire my community to learn about ALS”: Jane’s story
- “While I still can, I will focus on what’s possible”: Steve’s story
- “While I still can, I will cherish my time with my children”: Anne-Marie’s story
- From scientific curiosity to a breakthrough ALS research discovery
- Going for gold: Researchers open the blood-brain barrier for better drug delivery
- Pushing boundaries in medical imaging to explore new pathways for ALS treatment
- Raise your hand in support of continuing to build Canada as a primary destination for ALS clinical trials
- Discovery Grant gives lab capacity to deepen its focus on ALS
- 2022 ALS Canada Research Forum fosters continued collaboration in the research community
- Novel collaborations could lead to more effective ways to treat patients with ALS
- How “accidental” discoveries can lead to new insights in ALS biology
- What a new mouse model can teach us about weight loss, metabolism, and ALS
- A powerful collaboration offers crucial insights at the frontier of ALS biology
- Truth may literally be in the eye of the beholder
- Truth may literally be in the eye of the beholder
- In the face of hardship and an ALS diagnosis, love persists
- No stranger to adversity, Susheela faced ALS with courage
- Steve may have lost his singing voice, but he hasn’t lost hope
- How does a new experimental treatment for ALS behave within the body?
- Is there a link between metabolism and ALS disease progression?
- How does the loss of the normal function of DNAJC7 cause ALS?
- Can zebrafish help explain how mutations in this gene contribute to ALS?
- Is it possible to target the root cause of ALS linked to the C9orf72 gene?
- Could mindfulness improve quality of life for people living with ALS?
- Loss and healing: A 900-km bike ride to drive ALS awareness
- ALS Canada’s 2021 Research Forum: Bringing together the research and patient community virtually
- A single mom living with ALS has high hopes for Lou Gehrig Day
- Could inflammation in this pathway provide a new target for ALS therapies?
- Lou Gehrig Day: A call to action from a former NHLer
- A family of Blue Jays fans cheers on Lou Gehrig Day
- Giving the gift of hope with a gift of tomorrow
- Share your baseball story
- The power of one, the value of many: Celebrating ALS Canada’s volunteers
- The Brain-Gut connection: Could a probiotic help delay the onset or severity of ALS symptoms?
- Maintaining dignity, independence and safety through ALS Canada’s Equipment Loan Program
- For What Counts: ALS Canada’s 2019 Annual Report
- Celebrating the strength of ALS Canada’s volunteer community
- Luckiest of the unlucky: keeping a positive mindset in the face of ALS
- Can an animal model provide new insights into the formation of stress granules?
- ALS Canada: Committed to the bright future of Canada’s ALS researchers
- Can new understandings about nuclear speckles lead to new treatment options for ALS?
- Could newly discovered tags on TDP-43 protein explain its abnormal behaviour in ALS?
- Is the loss of normal function of C9orf72 protein in a particular cell type a key driver of ALS disease processes?
- What is the role of a newly discovered protein in ALS?
- Is an experimental drug that can prevent abnormal protein behaviour in ALS already out there?
- Giving back honours a father’s sacrifice and untimely passing
- From ice bucket to bucket list: how Margot is coping with ALS
- Leading Canadian ALS researcher stresses “time is of the essence”
- No time to lose: ALS Canada volunteer and fundraiser sees urgent need for change
- Learning about ALS for the first time: young people share their perspectives
- Can the key to slowing ALS progression be found in the immune cells of the brain?
- Partnering with the ALS community on a new assessment tool
- Can new understandings about RNA granules explain types of ALS?
- Does a previously unstudied protein play an important role in ALS?
- Celebrating Your Impact: ALS Canada Volunteers
- Can antibodies help diagnosis ALS faster?
- Does a viral infection play a role in ALS onset and progression?
- Can Advanced Brain Imaging Diagnose ALS Earlier?
- Could decreasing the over-excitability of motor neurons be a new way to treat ALS?
- Do newly-discovered alternative proteins play a role in ALS?
- Cutting-edge technology allows University of Toronto researchers to tackle ALS in a new way
- Can a revolutionary gene-editing tool create better animal models for studying ALS?
- How are two of the most common occurrences in ALS related?
- Can measuring “biological age” explain why ALS affects people differently?
- Wrapping up the holiday giving season
- ALS took Eddy’s voice – today he has it back again
- Can environmental impacts on genes explain why ALS affects people differently?
- Every August Until A Cure 2018
- Mother and daughter caregiving team reach out with love and compassion
- Enduring love of a ‘forever husband’ inspires hope
- A Caregiver’s Story, Part 3: Looking forward, looking back
- A Caregiver’s Story, Part 2: Speaking out against the helplessness of ALS
- A Caregiver’s Story, Part 1: Championing the ALS cause
- How it feels knowing your daughter has ALS
- Richard and Heather leave gifts of hope for the future
- Can microscopic bubbles in our blood deliver ALS therapies effectively?
- A message from ALS Canada to our volunteers
- Young fundraisers making a big impact
- National Volunteer Week | Debbie Damario and Ashley Dunseith
- National Volunteer Week | Judith Malvern
- Shining a light on volunteerism across the board
- Can insights about why eye muscles are resistant to ALS help preserve function in other muscles?
- Leveraging scientific advancements and open science to study ALS progression
- Could studying yeast help to answer questions about how ALS progresses?
- Could touchscreen technology improve testing for cognitive impairment in ALS?
- Comparing DNA profiles of Canadians with a similar heritage
- Can a guardian protein protect motor neurons from toxicity in ALS?
- Can probiotics play a protective role in ALS?
- Understanding if and how the body compensates for motor neuron loss in ALS
- Talking about ALS with friends and family poses special challenges for caregivers
- Can a promising drug combination address one of the most defining biological characteristics of ALS?
- Strengthening Canada’s Excellence in ALS Clinical Trials
- The power of connection – one family’s experience with ALS
- ALS researchers respond to the Ice Bucket Challenge
- Bench Strength: The Power of Collaboration Fuels Canada’s ALS Research
- Dr. Christen Shoesmith discusses the importance of donor support
- Eric Martineau: ALS Researcher Profile
- Audrey Labarre: ALS Researcher Profile
- Elsa Tremblay – ALS and the Neuromuscular Junction
- Pimozide: Everything Old is New Again
- Dr. Christen Shoesmith – ALS Best Practice Recommendations
- From Inquiry to Insight: Dr. Michael Strong
- Every August Until A Cure
- Bastien Paré: Skin models for the study of ALS
- Learning more about how gene mutations can cause ALS
- For Tom and Denis, the Ice Bucket Challenge is Personal
- Could viruses play a role in the onset or progression of ALS in people with a genetic link?
- Dr. Richard Bedlack’s Quest for ALS Discovery: The Truth is Out There
- The ALS Canada Research Program
- Paying it forward to benefit people with ALS in the future
- “When you are loved, you have everything:” ALS Canada ambassador Eddy Lefrançois reflects on 25 years living with ALS
- National Family Caregiver Day: A conversation with ALS Caregiver Jonathan Corber
- ALS societies across Canada mourn the loss of Mauril Bélanger
- ALS community challenges Canada to take the ALS Ice Bucket Challenge
- Where your dollars went from the 2014 ALS Ice Bucket Challenge